Page 11 - Cancer

Tata Memorial Centre aims to double share in cancer treatment by 2030

Tata Memorial Centre (TMC) is aiming to double its share of cancer patients it serves per year to 20 per cent of the total number of such patients in the country by 2030 from the present 10 per cent, its director Rajendra Badwe said on Friday. Currently, the centre provides treatment to 10 per cent of the country's total cancer patients per year. The premier cancer treatment and research institute, backed by Tata Group and the government, is expanding facilities and educational capabilities to train the manpower, which will be required to achieve the target, Badwe told reporters here. "Presently, India has about 13 lakh cancer patients every year, 10 per cent of those are treated at Tata Hospital. We would like that to be doubled to somewhere about 20 per cent of the total national problem," the director said, adding that the aim to double is being sought to be achieved by the end of the decade. He said the hospital feels there will be a huge increase in the total number of patient

AstraZeneca announces launch of cancer medication Tremelimumab in UAE

AstraZeneca has announced the launch of its revolutionary cancer medication, IMJUDO (tremelimumab) in the UAE

Pfizer pouring windfall profits from Covid-19 vaccine into cancer battle

The U.S. government will end the COVID Public Health Emergency on Thursday that allowed millions of Americans to receive vaccines, tests and treatments at no cost

Covid-19 dropped to fourth leading cause of death in US last year

U.S. deaths fell last year, and COVID-19 dropped to the nation's No. 4 cause, the Centers for Disease Control and Prevention reported Thursday. COVID-19 deaths trailed those caused by heart disease, cancer and injuries such as drug overdoses, motor vehicle fatalities and shootings. In 2020 and 2021, only heart disease and cancer were ahead of the coronavirus. U.S. deaths usually rise year-to-year, in part because the nation's population has been growing. The pandemic accelerated that trend, making 2021 the deadliest in U.S. history, with more than 3.4 million deaths. But 2022 saw the first drop in deaths since 2009. The 2022 tally was about 3.3 million a 5 per cent decline from 2021 but still much higher than in the years before the pandemic. The CDC cautioned that last year's numbers are preliminary and may change a little after further analysis. Coronavirus-associated death rates fell for nearly all Americans. The virus was deemed the underlying cause of about 187,000 U.S. death

Unleashing the potential of immunology to improve public health

.

J&J, cancer victims ordered to start settlement talks in bankruptcy

A federal judge ordered a new round of settlement talks between Johnson & Johnson and lawyers who spurned the company's offer to pay $8.9 billion to end tens of thousands of cancer claims

J&J accused by US of misusing bankruptcy to end talc cancer suits

J&J has an $8.9 billion settlement agreement with the "vast majority" of the law firms representing talc claimants, said the company's head of litigation

J&J accused by US of misusing bankruptcy to end talc cancer suits

The healthcare products maker is trying for the second time to get itself out of a jam as cheaply as possible, using the Chapter 11 filing of LTL Management

Easily spread virus exploits genomic weaknesses, causes cancer: Study

Researchers have described in a study how the Epstein-Barr virus (EBV), the ubiquitous virus easily spread through bodily fluids, not only exploits genomic weaknesses to cause cancer, but also reduces the body's ability to suppress it. The researchers at the University of California (UC) San Diego, US, said that more than 90 per cent of the world's population has been infected by the EBV, usually during childhood, and that while most of the infections it causes are mild and pass, the virus persists in the body, becoming latent or inactive, sometimes reactivating. The EBV spreads easily through bodily fluids, primarily saliva, through activities such kissing, sharing drinks or using the same eating utensils. The researchers' findings showed "how a virus can induce cleavage of human chromosome 11, initiating a cascade of genomic instability that can potentially activate a leukemia-causing oncogene and inactivate a major tumour suppressor," said senior study author Don Cleveland, ...

Indian startup PredOmix develops AI-based blood test to detect 32 cancers

The company's OncoVeryx-F is a patented technology that combines metabolomics (study of small molecules) and AI to identify metabolite signatures of multiple cancers in a single test

BioNTech signs deal to co-develop OncoC4's cancer antibody drug

A late-stage trial for the drug has been planned for this year, the companies said

Pfizer to acquire Seagen for $43 bn to deepen reach into treating cancer

Pfizer will spend USD 43 billion to buy Seagen and deepen its reach into treating cancer. The pharmaceutical giant said Monday that it will pay USD 229 per Seagen share. Together, Pfizer and Seagen seek to accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining the power of Seagen's antibody-drug conjugate (ADC) technology with the scale and strength of Pfizer's capabilities and expertise," Pfizer Chairman and CEO Dr. Albert Bourla said in a statement. Bothell, Washington-based Seagen Inc. is a biotech drug developer. Its key products use monoclonal antibodies that bind to the surface of a tumour cell to deliver a cancer-killing agent while sparing surrounding healthy tissue. Monoclonal antibodies are lab-made proteins delivered mostly by IV at an infusion center, according to the Cleveland Clinic. Seagen's top seller, Adcetris, treats lymph system cancers. It brought in USD 839 million in sales last year, a 19 per cent increase over

No link between use of ranitidine and cancer risk: Nature study

Ranitidine has been in existence for over four decades and has been on the WHO list of essential medicines for several years

For insurance cover against cancer, maintain high sum for hospitalisation

February 4 is World Cancer Day: here is advice on how meet ancillary expenses in treating disease

World Cancer Day: WHO calls for action for prevention, early detection

On World Cancer Day, World Health Organization (WHO) has called for intensified action across the Southeast Asian region to strengthen health systems to prevent and detect cancers early.

Tata Capital Healthcare Fund infuses $ 10 mn in Mumbai Oncocare Centre

MOC, a unit of Cellcure Cancer Center Pvt Ltd, plans to utilise the newly infused capital to expand across India in next 18 months, the company said in a statement

After WHO's warning on cancer link, a look at how India consumes alcohol

According to NFHS-5, alcohol consumption is higher in rural parts of the country than the urban areas

No amount of alcohol 'safe', even low consumption hikes cancer risk: WHO

The agency has previously found that alcohol causes at least 7 types of cancer, including the most common cancer types, such as bowel cancer and female breast cancer

Researchers take closer look at DNA repair scheme for cancer therapy

Researchers from Rice University and St. Jude Children's Research Hospital in Memphis, Tennessee, have taken a closer look at one of the ways cells repair broken strands of DNA.They discovered details that could help make a particular enzyme a promising target for precision cancer therapy.Not unlike patching a tire, the job of DNA polymerase theta (aka Pol theta) is to fix double-strand breaks in DNA, bridging the hanging single-stranded ends and catalyzing DNA synthesis across the break, a process known as microhomology-mediated end joining (MMEJ).MMEJ is complementary to two other processes -- homologous recombination and non-homologous end joining -- that repair DNA double-strand breaks, but with lower fidelity because Pol theta is prone to mutation, insertion, and deletion errors.But therein lies the advantage: MMEJ needs Pol theta to repair a double strand.A new study by Rice and St. Jude's researchers in the journal Nucleic Acids Research reveals for the first time the ...

Tennis legend Martina Navratilova diagnosed with throat, breast cancer

Tennis great Martina Navratilova said on Monday that she has been diagnosed with throat cancer and breast cancer. In a statement released by her representative, the 18-time Grand Slam singles champion and member of the International Tennis Hall of Fame said her prognosis is good and she will start treatment this month. "This double whammy is serious but still fixable, and I'm hoping for a favourable outcome," the 66-year-old Navratilova said. "It's going to stink for a while but I'll fight with all have I got." She said she noticed an enlarged lymph node in her neck while attending the season-ending WTA Finals in Fort Worth, Texas, in November, and a biopsy showed early stage throat cancer. While Navratilova was undergoing tests on her throat, she said, the unrelated breast cancer was discovered. Navratilova was diagnosed with a noninvasive form of breast cancer in 2010 and had a lumpectomy. She won 59 Grand Slam titles overall, including 31 in women's doubles and 10 in mixed dou